Tradestie Institutional Equity Comparison Engine

NTLA vs PACB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PACB Overall Edge

PACB Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pacific Biosciences of California, Inc. (PACB) driven by superior Growth & Margin, Momentum & Technical while NTLA counters with relative strength in Options & Structure. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NTLA N/M vs PACB N/M Fwd P/E
Growth & Margin Winner PACB
Op Margin -826.0% vs -333.0% ยท YoY -48.0% vs +5.5%
Momentum & Technical Winner PACB
1Y +15.3% vs +15.6% ยท 52W Pos 20% vs 34%
Options & Structure Winner NTLA
BREAKDOWN (78th %ile IV) vs BREAKDOWN (47th %ile IV)
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
1M Return -12.43%
1Y Return +15.34%
Forward P/E N/M
Unified AI Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
1M Return +8.96%
1Y Return +15.64%
Forward P/E N/M
Unified AI Score
38.0 / 100 SELL
Tech 15.0 Fund 35.0 Flow 57.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NTLA +15.34% PACB +15.64% Spread: +0.3 pp (PACB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NTLA Revenue PACB Revenue NTLA Op. Margin PACB Op. Margin Margin Edge
FY2018 $30M $80M -298.6% -128.4% PACB
FY2019 $40M $90M -246.8% -110.6% PACB
FY2020 $60M $80M -235.5% -132.3% PACB
FY2021 $30M $130M -810.4% -161.2% PACB
FY2022 $50M $130M -879.0% -239.4% PACB
FY2023 $40M $200M -1420.5% -166.8% PACB
FY2024 $60M $150M -923.1% -308.0% PACB
FY2025 $70M $160M -651.7% -346.2% PACB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NTLA (5) vs PACB (3)
Institutional Metric NTLA PACB Criterion Row Winner
Market Capitalization Scale $1.5B $615.1M Larger Scale NTLA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -48.0% +5.5% Higher Growth PACB
Operating Margin (TTM) Profitability -826.0% -333.0% Higher Margin PACB
Net Profit Margin Profitability 0.0% -81.3% Higher Margin NTLA
Return on Equity (ROE) Capital Efficiency -62.6% -929.3% Higher ROE NTLA
52-Week Range Position Momentum 20% ($8โ€“$18) 34% ($1โ€“$3) Stronger Trend PACB
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 87% Vol 2.27ฮฒ ยท 112% Vol Lower Realized Risk NTLA
Unified Institutional Score Composite Signal 49.9 / 100 (HOLD) 38.0 / 100 (SELL) Higher Composite NTLA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NTLA vs PACB Buy Guide
NTLA BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 78th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live NTLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 47th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PACB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NTLA nor PACB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.